Table 2.
Activity of ICZ against different HCMV strains.
| HCMV Strain | Drug resistance | ICZ EC50a (μM), CIb | Controlc EC50 (μM), CI |
|---|---|---|---|
| TB40 | None | 4.44 (2.47–7.63) | N.D. |
| VR1814 | None | 5.13 (2.48–9.89) | N.D. |
| 388438U | None | 3.88 (1.49–8.96) | N.D. |
| PFArD100 | FOS, ACV | 5.21 (2.38–10.84) | 278 (241–312) |
| GDGrP53 | GCV, CDV | 6.17 (3.14–11.56) | 74.4 (42.4–145.5) |
N.D., Not Determined. ACV, acyclovir; CDV, cidofovir.
a
50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFF cells. Reported values represent data derived from n ≥ 3 independent experiments in duplicate.
b
CI, Confidence Interval (95% Profile likelihood, calculated with Graphpad Prism 8.0 software).
c
GCV was used for GDGrP53 and FOS for PFArD100.